The Asia Pacific Cartilage Repair Market would witness market growth of 9.8% CAGR during the forecast period (2018 – 2024).
When damage is caused in the cartilage, it restricts the regular movement of the knee, causing immense pain. It generally occurs after a traumatic and twisting injury to the knee. If cartilage damage remains untreated, it would lead to knee replacement surgery. The tissue prevents friction between the bones, by absorbing shock in the joints. Asia-Pacific has huge growth potential and would grow at a notable rate during the forecast period. The growth is primarily attributed to the technological advancement in the field of cartilage surgery and swift rise in demand primarily in developing countries such as Japan and China. Moreover, Emerging markets are a highly potential market; therefore, vendors are majorly focusing on Asia-Pacific for expansion activities.
Based on Modality, the market is segmented into Cell based and Non-Cell based. Based on Treatment type, the market is segmented into Intrinsic Repair Stimulus and Palliative. Based on Application, the market is segmented into Fibrocartilage and Hyaline Cartilage. Based on Site outlook, the market is segmented into Knee Cartilage and Other site outlook. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include B. Braun Melsungen AG, Zimmer Biomet, Johnson and Johnson, Smith & Nephew Plc., Stryker Corporation, Vericel Corporation, Osiris Therapeutics Inc., Arthrex, Inc., Collagen Solutions Plc., and Anika Therapeutics, Inc.